当前位置: 首页 > 详情页

Fibroblast Growth Factor 11 (FGF11) Promotes Progression and Cisplatin Resistance Through the HIF-1 & alpha;/FGF11 Signaling Axis in Ovarian Clear Cell Carcinoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Natl Clin Res Ctr Obstet & Gynecol Dis, Dept Obstet & Gynecol, Beijing, Peoples R China [2]Capital Med Univ, Xuanwu Hosp, China Int Neurosci Inst CHINA INI, Neurospine Ctr,Natl Ctr Neurol Disorders, Beijing, Peoples R China
出处:
ISSN:

关键词: ovarian clear cell carcinoma cisplatin chemoresistance FGF11 HIF-1 & alpha

摘要:
Background: A poor prognosis is often associated with ovarian clear cell carcinoma (OCCC) due to its relative resistance to platinum-based chemotherapy. Although several studies have been launched to explore the pathogenesis of OCCC, the mechanism of chemoresistance has yet to be uncovered.Methods: Nanostring nCounter PanCancer Pathways Panel was performed to explore the expression profiles of OCCC tissues from patients showing different platinum sensitivity. Bioinformatic analysis was performed to select genes associated with chemoresistance and cell function assays, including colony formation, wound healing, transwell and flow cytometric analysis, were used to explore the role of the target gene in the progression of OCCC and resistance to cisplatin (DDP).Results: Gene expression profiles and bioinformatic analysis verified that the expression of fibroblast growth factor 11 (FGF11) was significantly increased in platinum-resistant OCCC tissues and increased FGF11 expression was related to poorer survival. Downregulation of FGF11 inhibited the proliferation, migration, and invasion, reversing the DDP resistance of OCCC cells. Mechanically, FGF11 was regulated by hypoxia-inducible factor-1a (HIF-1a) to modulate the DDP sensitivity.Conclusion: FGF11 was highly expressed in platinum-resistant OCCC tissues, promoting progression and resistance to DDP through the HIF-1a/FGF11 signaling axis.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2021]版:
Q3 ONCOLOGY
最新[2024]版:
Q3 ONCOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Natl Clin Res Ctr Obstet & Gynecol Dis, Dept Obstet & Gynecol, Beijing, Peoples R China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:17659 今日访问量:0 总访问量:938 更新日期:2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院